<DOC>
	<DOCNO>NCT01406483</DOCNO>
	<brief_summary>The primary objective exploratory cohort study describe level platelet reactivity patient thienopyridine await coronary artery bypass grafting ( CABG ) .</brief_summary>
	<brief_title>Platelet Reactivity Patients Thienopyridine Awaiting Coronary Artery Bypass Grafting</brief_title>
	<detailed_description>The recent emergence platelet reactivity test potential option evaluate degree platelet inhibition promise add another level understand concept CABG-related bleeding . There emerge literature link high level platelet reactivity adverse clinical event , primarily patient clopidogrel . For example , study VerifyNow P2Y12 platelet function assay show Platelet Reactivity Units ( PRU ) &gt; 235-240 patient clopidogrel therapy appear predict cardiovascular events.15,16 There paucity literature , however , use platelet reactivity test predict bleed event complication . In word , excessively high level platelet reactivity predict ischemic event , excessively low level platelet reactivity predict bleed event ? This especially relevant question , give emergence prasugrel therapeutic option . The investigator therefore propose exploratory cohort study patient receive thienopyridine ( clopidogrel prasugrel ) undergo CABG , order describe level platelet reactivity patient use variety platelet function test .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Hematoma</mesh_term>
	<mesh_term>Postoperative Hemorrhage</mesh_term>
	<mesh_term>Blood Loss , Surgical</mesh_term>
	<criteria>1 . Patients â‰¥ 18 year old gender . 2 . Taking maintenance thienopyridine therapy within 5 day surgery OR receive load dose thienopyridine therapy within 48 hour surgery CABG . 3 . Referred CABG ( schedule perform current admission ) . 1 . Known allergy aspirin , clopidogrel , prasugrel . 2 . Use glycoprotein ( GP ) IIb/IIIa inhibitor within 8 hour initial platelet reactivity test . 3 . Patient know pregnant lactating . 4 . Patient known history bleed diathesis currently active bleeding . 5 . Platelet count &lt; 100,000/mm day initial blood draw . 6 . Hematocrit &lt; 25 % day initial blood draw . 7 . On warfarin therapy time initial blood draw . 8 . Known blood transfusion within precede 10 day blood draw . 9 . Patients treat nonsteroidal antiinflammatory drug ( NSAIDS ) within previous 5 day . 10 . Plan patient discharge undergoing CABG . 11 . Any significant medical condition , investigator 's opinion , may interfere patient 's optimal participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Platelet reactivity</keyword>
	<keyword>CABG</keyword>
	<keyword>Perioperative hospital bleeding</keyword>
</DOC>